Speaker Profile

Ph.D., Vice President of Sales and Marketing, Myriad RBM, Inc.

Dr. Eisinger is a member of the executive management team at Myriad RBM, a leading multiplexed immunoassay testing laboratory providing comprehensive protein biomarker services for drug development within a CLIA certified laboratory. He directs sales, marketing, and business development in the therapeutic areas of immuno-oncology, oncology, autoimmune, metabolic, CNS and CVD applications. Dr. Eisinger joined Myriad RBM in 2006 when RBM acquired Multiplex Biosciences, a multiplex immunoassay development and manufacturing company he started and lead as President and CEO. He has over 22 years of industry leadership experience in various R&D, operational, and commercialization roles. Dr. Eisinger has B.S. in biochemistry from Cornell University and a PhD in stem cell molecular biology from the University of Vermont prior to completing post-doctoral training at Dartmouth Medical School.

Immunotherapy Showcase: Myriad RBM, Inc.
Myriad RBM, Inc. is a CLIA certified, multiplexed immunoassay testing laboratory.

Circulating IL-8: A New Response Predictor for Immunotherapies
Utilizing 2 immunoassay platforms validated to clinical laboratory standards for quantifying circulating proteins from immunotherapy clinical trial patients, select pharmacodynamic and prognostic biomarker findings will be presented including the discovery of IL-8 as a biomarker and therapy target.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.